Our Top Research Highlights of 2022
2022 has been an amazing year for progress and growth for the T1D Exchange team. In the past year, the…
Our Research: Young People with T1D + Other Conditions Face Higher Risk of Severe Covid-19
Our research ā recently highlighted by the American Diabetes Association and Healio ā continues to demonstrate that children and young…
When Diabetes Clinics Collaborate: People with Type 1 Diabetes Reap the Benefits
With nearly 2 million people across the country living with type 1 diabetes (T1D) and thousands of endocrinology clinics, collaboration…
Reaching A1c Goals: Research Says These Factors Matter Most
Your HbA1c (A1c) is one part of your toolkit as a person with type 1 diabetes (T1D). This number cannot…
Enhancing Equity for People with Type 1 Diabetes
The COVID-19 pandemic heightened awareness of pervasive healthcareĀ inequities in the United States. Race, education, economic status, and other āsocial determinants…
FDA Approves First Drug to Delay the Full Onset of Type 1 Diabetes
The FDA approval of teplizumab ā brand name Tzield āĀ was announced today on November 17, 2022 for use in people…
Chatting about the T1D Exchange Registry: Q&A with the Team
Thinking about signing up for the T1D Exchange Registry, or already registered but not sure what is next? We sat…
Scientific Research, T1D, and You: What is it and why care?
Iām a scientist. I design and run research studies ā usually, those with a psychological or social twist ā for…
Investigating Factors that Worsen Diabetes Care in the U.S.
āIn the past two years, weāve all been faced with multiple challenges from the COVID-19 pandemic to rising health inequities,ā…
T1D Exchange Research Featured at ISPAD 2022: All About Device Use
We are honored to share recent work from the T1D Exchange Quality Improvement Collaborative (T1DX-QI) at the 48th Annual International…